These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38735433)

  • 61. Limited Value of Bladder Wash Cytology During Follow-Up of Patients With Non-muscle Invasive Bladder Cancer.
    Bieri U; Kranzbühler B; Wettstein MS; Fankhauser CD; Kaufmann BP; Seifert B; Bode PK; Poyet C; Lenggenhager D; Hermanns T
    Cureus; 2023 Jun; 15(6):e40283. PubMed ID: 37448431
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
    Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
    J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The efficacy and reliability of VI-RADS in determining candidates for repeated transurethral resection in patients with high-risk non-muscle invasive bladder cancer.
    Erkoc M; Otunctemur A; Bozkurt M; Can O; Atalay HA; Besiroglu H; Danis E; Degirmentepe RB
    Int J Clin Pract; 2021 Sep; 75(9):e14584. PubMed ID: 34185372
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.
    Rink M; Babjuk M; Catto JW; Jichlinski P; Shariat SF; Stenzl A; Stepp H; Zaak D; Witjes JA
    Eur Urol; 2013 Oct; 64(4):624-38. PubMed ID: 23906669
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Xpert Bladder Cancer Monitor for the Early Detection of Non-Muscle Invasive Bladder Cancer Recurrences: Could Cystoscopy Be Substituted?
    Lozano F; Raventós CX; Carrion A; Dinarés C; Hernández J; Trilla E; Morote J
    Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509344
    [TBL] [Abstract][Full Text] [Related]  

  • 66. ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes.
    Racioppi M; Di Gianfrancesco L; Ragonese M; Palermo G; Sacco E; Bassi PF
    BMC Cancer; 2018 Dec; 18(1):1224. PubMed ID: 30522445
    [TBL] [Abstract][Full Text] [Related]  

  • 67. In the cystoscopic follow-up of non-muscle-invasive transitional cell carcinoma, NMP-22 works for high grades, but unreliable in low grades and upper urinary tract tumors.
    Coskuner E; Cevik I; Ozkan A; Dillioglugil O; Akdas A
    Int Urol Nephrol; 2012 Jun; 44(3):793-8. PubMed ID: 22371126
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey.
    Nielsen ME; Smith AB; Pruthi RS; Guzzo TJ; Amiel G; Shore N; Lotan Y
    BJU Int; 2012 Oct; 110(7):967-72. PubMed ID: 22487336
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The Value of Negative Urinary Dipstick Tests for Haematuria in Patients Undergoing Surveillance for Low-grade Ta Urothelial Cancer: A Two-stage Prospective Clinical Study in 524 Patients.
    Shah CP; Lord-McKenzie T; Makris A; Trail M; Gray J; Smith G; Mariappan P
    Eur Urol Open Sci; 2024 Feb; 60():24-31. PubMed ID: 38375346
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Novel urinary biomarkers for the detection of bladder cancer: A systematic review.
    Tan WS; Tan WP; Tan MY; Khetrapal P; Dong L; deWinter P; Feber A; Kelly JD
    Cancer Treat Rev; 2018 Sep; 69():39-52. PubMed ID: 29902678
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A Genomic Urine Assay for Surveillance of Patients with Bladder Cancer Treated with Radiotherapy.
    de Jong FC; Iflé IG; van der Made AC; Kooper D; de Jong JJ; Franckena M; Zuiverloon TCM; van Criekinge W; Incrocci L; Zwarthoff EC; Boormans JL
    Eur Urol Open Sci; 2024 Apr; 62():131-139. PubMed ID: 38496820
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pediatric urothelial bladder neoplasm.
    Galiya R; Stanislav K; Jawdat J; Benjamin H; Boris C
    J Pediatr Urol; 2022 Dec; 18(6):833.e1-833.e4. PubMed ID: 35871900
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer.
    Valenberg FJPV; Hiar AM; Wallace E; Bridge JA; Mayne DJ; Beqaj S; Sexton WJ; Lotan Y; Weizer AZ; Jansz GK; Stenzl A; Danella JF; Shepard B; Cline KJ; Williams MB; Montgomery S; David RD; Harris R; Klein EW; Bradford TJ; Wolk FN; Westenfelder KR; Trainer AF; Richardson TA; Egerdie RB; Goldfarb B; Zadra JA; Ge S; Zhao S; Simon IM; Campbell SA; Rhees B; Bates MP; Higuchi RG; Witjes JA
    Eur Urol; 2019 May; 75(5):853-860. PubMed ID: 30553612
    [TBL] [Abstract][Full Text] [Related]  

  • 74. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
    Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M;
    Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Usefulness of the Urine Methylation Test (Bladder EpiCheck
    Peña KB; Riu F; Hernandez A; Guilarte C; Badia J; Parada D
    J Clin Med; 2022 Jul; 11(13):. PubMed ID: 35807141
    [TBL] [Abstract][Full Text] [Related]  

  • 76. ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer.
    Monteiro LL; Witjes JA; Agarwal PK; Anderson CB; Bivalacqua TJ; Bochner BH; Boormans JL; Chang SS; Domínguez-Escrig JL; McKiernan JM; Dinney C; Godoy G; Kulkarni GS; Mariappan P; O'Donnell MA; Rentsch CA; Shah JB; Solsona E; Svatek RS; van der Heijden AG; van Valenberg FJP; Kassouf W
    World J Urol; 2019 Jan; 37(1):51-60. PubMed ID: 30109483
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Investigation of Atypical Cell Parameter in the Surveillance of Patients with NMIBC; Initial Outcomes of a Single Center Prospective Study.
    Karaburun MC; Özkaya MF; Ergüder Bİ; Süer E
    J Med Syst; 2023 Mar; 47(1):41. PubMed ID: 36976368
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The role of URO17® in diagnosis and follow up of bladder cancer patients.
    Ibrahim M; Rabinowitz J; Hilbert R; Ghose A; Agarwal S; Swamy R; Bulut I; Guttierrez M; Buali E; Nassar E; Jhavar P; Al-Hashimi F; Vasdev N
    BMC Urol; 2024 Feb; 24(1):34. PubMed ID: 38336681
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Repeated 5-aminolevulinic Acid Instillations During Follow-up in Non-muscle-invasive Bladder Cancer: A Randomized Study.
    Kelloniemi E; Järvinen R; Hellström P; Rintala E; Aaltomaa S; Isotalo T; Innos K; Kaasinen E
    In Vivo; 2021; 35(3):1561-1568. PubMed ID: 33910836
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical utility of vesical imaging-reporting and data system (VI-RADS) in non-muscle invasive bladder cancer (NMIBC) patients candidate for en-bloc transurethral resection: A prospective study.
    El-Karamany TM; Al-Adl AM; Hosny MM; A Eldeep H; El-Hamshary SA
    Urol Oncol; 2022 Oct; 40(10):454.e1-454.e7. PubMed ID: 35466036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.